Stryker Corporation $SYK Shares Sold by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC cut its holdings in shares of Stryker Corporation (NYSE:SYK) by 17.6% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 80,254 shares of the medical technology company’s stock after selling 17,151 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Stryker were worth $25,267,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of SYK. Varma Mutual Pension Insurance Co boosted its holdings in Stryker by 10.5% in the fourth quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock valued at $18,842,000 after purchasing an additional 5,100 shares during the last quarter. QRG Capital Management Inc. grew its position in Stryker by 7.4% during the 4th quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock worth $21,281,000 after purchasing an additional 4,186 shares during the period. Swedbank AB raised its stake in shares of Stryker by 6.6% during the 4th quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock valued at $45,349,000 after buying an additional 7,934 shares during the last quarter. Crossmark Global Holdings Inc. lifted its holdings in shares of Stryker by 31.1% in the 4th quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock valued at $9,426,000 after buying an additional 6,367 shares during the period. Finally, Royal Bank of Canada boosted its stake in shares of Stryker by 6.5% in the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after buying an additional 199,863 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SYK has been the topic of several analyst reports. BMO Capital Markets assumed coverage on Stryker in a report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 target price on the stock. Barclays decreased their price target on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a report on Monday, May 4th. Evercore set a $350.00 price objective on shares of Stryker in a research note on Monday, July 6th. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Finally, UBS Group initiated coverage on shares of Stryker in a research note on Tuesday, July 28th. They issued a “buy” rating and a $400.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Stock Down 0.7%

Shares of NYSE SYK opened at $338.80 on Friday. The firm has a market cap of $129.95 billion, a price-to-earnings ratio of 35.11, a price-to-earnings-growth ratio of 2.16 and a beta of 0.76. The company’s 50-day simple moving average is $324.61 and its 200-day simple moving average is $333.57. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts predict that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. Stryker’s dividend payout ratio is presently 36.48%.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.